rs148475405
Positions:
Variant summary
Our verdict is Benign. Variant got -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BS1BS2
The NM_001114753.3(ENG):c.159C>T(p.Cys53Cys) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000349 in 1,614,236 control chromosomes in the GnomAD database, including 4 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Genomes: 𝑓 0.00068 ( 1 hom., cov: 30)
Exomes 𝑓: 0.00031 ( 3 hom. )
Consequence
ENG
NM_001114753.3 synonymous
NM_001114753.3 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: -1.38
Genes affected
ENG (HGNC:3349): (endoglin) This gene encodes a homodimeric transmembrane protein which is a major glycoprotein of the vascular endothelium. This protein is a component of the transforming growth factor beta receptor complex and it binds to the beta1 and beta3 peptides with high affinity. Mutations in this gene cause hereditary hemorrhagic telangiectasia, also known as Osler-Rendu-Weber syndrome 1, an autosomal dominant multisystemic vascular dysplasia. This gene may also be involved in preeclampsia and several types of cancer. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2013]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -21 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.75).
BP6
Variant 9-127843154-G-A is Benign according to our data. Variant chr9-127843154-G-A is described in ClinVar as [Likely_benign]. Clinvar id is 237021.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr9-127843154-G-A is described in Lovd as [Benign].
BP7
Synonymous conserved (PhyloP=-1.38 with no splicing effect.
BS1
Variant frequency is greater than expected in population eas. gnomad4 allele frequency = 0.000683 (104/152354) while in subpopulation EAS AF= 0.0189 (98/5182). AF 95% confidence interval is 0.0159. There are 1 homozygotes in gnomad4. There are 68 alleles in male gnomad4 subpopulation. Median coverage is 30. This position pass quality control queck.
BS2
High AC in GnomAd4 at 104 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ENG | NM_001114753.3 | c.159C>T | p.Cys53Cys | synonymous_variant | 2/15 | ENST00000373203.9 | NP_001108225.1 | |
ENG | NM_000118.4 | c.159C>T | p.Cys53Cys | synonymous_variant | 2/14 | NP_000109.1 | ||
ENG | NM_001406715.1 | c.159C>T | p.Cys53Cys | synonymous_variant | 2/8 | NP_001393644.1 | ||
ENG | NM_001278138.2 | c.-388C>T | 5_prime_UTR_variant | 2/15 | NP_001265067.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ENG | ENST00000373203.9 | c.159C>T | p.Cys53Cys | synonymous_variant | 2/15 | 1 | NM_001114753.3 | ENSP00000362299.4 | ||
ENG | ENST00000344849.4 | c.159C>T | p.Cys53Cys | synonymous_variant | 2/14 | 1 | ENSP00000341917.3 | |||
ENG | ENST00000480266.6 | c.-388C>T | 5_prime_UTR_variant | 2/15 | 2 | ENSP00000479015.1 |
Frequencies
GnomAD3 genomes AF: 0.000683 AC: 104AN: 152236Hom.: 1 Cov.: 30
GnomAD3 genomes
AF:
AC:
104
AN:
152236
Hom.:
Cov.:
30
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00160 AC: 403AN: 251438Hom.: 3 AF XY: 0.00153 AC XY: 208AN XY: 135896
GnomAD3 exomes
AF:
AC:
403
AN:
251438
Hom.:
AF XY:
AC XY:
208
AN XY:
135896
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000314 AC: 459AN: 1461882Hom.: 3 Cov.: 32 AF XY: 0.000303 AC XY: 220AN XY: 727244
GnomAD4 exome
AF:
AC:
459
AN:
1461882
Hom.:
Cov.:
32
AF XY:
AC XY:
220
AN XY:
727244
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000683 AC: 104AN: 152354Hom.: 1 Cov.: 30 AF XY: 0.000913 AC XY: 68AN XY: 74500
GnomAD4 genome
AF:
AC:
104
AN:
152354
Hom.:
Cov.:
30
AF XY:
AC XY:
68
AN XY:
74500
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
6
AN:
3478
ClinVar
Significance: Benign/Likely benign
Submissions summary: Benign:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Telangiectasia, hereditary hemorrhagic, type 1 Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jun 14, 2016 | - - |
ENG-related disorder Benign:1
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Mar 20, 2019 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
not provided Benign:1
Benign, criteria provided, single submitter | clinical testing | GeneDx | May 01, 2019 | - - |
Hereditary hemorrhagic telangiectasia Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 25, 2024 | - - |
Cardiovascular phenotype Benign:1
Benign, criteria provided, single submitter | clinical testing | Ambry Genetics | May 22, 2015 | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at